The given text snippets discuss the guidelines and recommendations for the use of ICS (inhaled corticosteroids) in the treatment of asthma. The GINA (Global Initiative for Asthma) guidelines suggest using low, medium, or high ICS doses for children and adults based on the severity of their asthma. The 2019 GINA strategy report is considered a significant change in asthma management, and it no longer recommends using ICS for safety reasons. For patients with difficult-to-treat asthma, referral for expert advice is recommended. Guidelines also suggest using lower initial ICS doses or a combination of ICS-LABA (long-acting beta2-agonists) with formoterol for maintenance and reliever therapy. The use of ICS is also categorized into minimal, low, medium, or high doses based on patient claims and response to therapy. However, a definitive diagnosis for asthma requires more than just symptoms and response to therapy.